Gut-Heart Link: Bile Acid Receptor Identified as Sleep Apnea Risk Factor

New research presented at the ASM Microbe 2026 conference has identified a critical biological pathway linking obstructive sleep apnea to cardiovascular disease. By studying mice, researchers discovered that the farnesoid X receptor (FXR)—a protein activated by bile acids—acts as a key driver in the development of arterial plaque when the body is subjected to the intermittent oxygen deprivation characteristic of sleep apnea.

Obstructive sleep apnea is known to disrupt systemic health by causing repeated breathing pauses, which alter bile acid composition and gut microbiome stability. The study revealed that when the FXR receptor was genetically disabled in mice prone to heart disease, the animals exhibited a marked reduction in fatty plaque buildup within their arteries. Furthermore, these mice showed greater resilience against the microbiome disturbances typically triggered by sleep apnea-like conditions.

This discovery is significant because it shifts the focus of cardiovascular risk management from traditional heart-centered treatments to the gut-liver axis. By understanding how gut microbes and bile acids communicate with the heart, clinicians may eventually develop targeted therapies that modulate this receptor or the microbiome to protect sleep apnea patients from heart disease. This research opens a promising new frontier in preventative medicine, suggesting that the key to heart health may reside in the complex chemical signaling occurring within the digestive system.